Scientific Online Resource System

Conference Proceedings

Treatment Of Infantile Hepatic Hemangiomas With Propranolol – A Clinical Case

Petar Shivachev, Miglena Georgieva, Kalina Ganeva

Abstract

Infantile hepatic hemangiomas are the most common benign tumors of the liver in childhood, which can sometimes lead to life-threatening complications and death. The therapeutic approach is different and includes: surveillance, interventional, surgical or drug treatment. In recent years, the drug of choice is propranolol. 

We present a clinical case of a two-month-old infant with multiple infantile cutaneous hemangiomas. An enlarged liver with multifocal hepatic hemangiomas was detected by ultrasound and computed tomography. No evidence of high cardiac output or heart failure was observed. The alpha-fetoprotein and thyroid-stimulating hormone levels were initially elevated. Propranolol solution was administered in weekly doses up to 3 mg/mg, twice daily. As early as the second month of starting treatment, regression of liver lesions was observed by echocardiography.

The present case confirms the positive effect of early treatment with propranolol in infantile hepatic hemangiomas, decreasing the lesions and preventing complications in the progression of the disease.


Keywords

hepatic hemangiomas, infantile hemangiomas, propranolol

Full Text


References

Gnarra M, Behr G, Kitajewski A, et al. History of the infantile hepatic hemangioma: From imaging to generating a differential diagnosis. World J Clin Pediatr 2016 August 8;5(3):273-280.

Zavras N, Dimopoulou A, Machairas N et al. Infantile hepatic hemangioma: current state of the art, controversies, and perspectives. Eur J Pediatr 179, 1–8 (2020).

International Society for the Study of Vascular Anomalies. ISSVA classification for vascular anomalies. 2018. Available at: https://www.issva.org/UserFiles/file/ISSVA-Classification-2018.pdf. Accessed June 9, 2019.

Rialon KL, Murillo R, Fevurly RD, et al. Risk factors for mortality in patients with multifocal and diffuse hepatic hemangiomas. J Pediatr Surg. 2015; 50(5):837–841

Lekwuttikarn R, Josephs S and Teng JM. Successful Medical Management of Life-threatening Hepatic Hemangioma in Neonates. Pediatrics October 2019, 144 (4) e20191339; DOI: https://doi.org/10.1542/peds.2019-1339

Iacobas I, Phung TL, Adams DM, et al. Guidance document for hepatic hemangioma (infantile and congenital) evaluation and monitoring. J Pediatr. 2018;203:294–300.e2

Itinteang T, Chibnall AM, Marsh R, et al. Elevated Serum Levels of Alpha Fetoprotein in Patients with Infantile Hemangioma Are Not Derived from within the Tumor. Front. Surg. 3:5. doi: 10.3389/fsurg.2016.00005.

Ji Y, Chen S, Yang K, et al. Screening for infantile hepatic hemangioma in patients with cutaneous infantile hemangioma: A multicenter prospective study. J Am Acad Dermatol 2021;84:1378-84.

Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013;131:128–40.

Lou Y, Peng WJ, Cao Y, et al. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol 2014;78:44–57.

Tian R, Liang Y, Wang J, et al. Propranolol for infantile hepatic hemangiendothelioma: Clinical evaluation of drug efficacy and safety using a single-center patient. Annals of Hepatology 19 (2020) 530–534 7.

Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651 [PMID: 18550886

Léauté-Labrèze С, Hoeger P., Mazereeuw-Hautier J., et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med, 372 (2015), pp. 735-746.


Refbacks

Font Size